Answers are grounded in this paper and cite their sources.
BACKGROUND: Chronic graft-versus-host disease (cGvHD) is a debilitating complication following allogeneic hematopoietic stem cell transplantation, often refractory to standard therapies. Belumosudil, a selective ROCK2 inhibitor with immunomodulatory and antifibrotic properties, has emerged as a targeted treatment option, gaining FDA approval for third-line therapy in 2021. However, its clinical efficacy and safety across diverse patient populations remain incompletely characterized. METHODS: We conducted a systematic review and meta-analysis of 16 studies encompassing 651 adult patients with cGvHD treated with belumosudil. Both prospective and retrospective studies reporting on overall response rate (ORR), organ-specific response, survival outcomes, and adverse events were included. Bayesian random-effects models were used to estimate pooled outcomes and assess heterogeneity. Meta-regression evaluated the impact of prior ruxolitinib exposure, disease severity, and lung involvement on treatment response. RESULTS: The pooled ORR was 60% (95% CI, 53 to 67), highest in prospective studies (73%) and lowest in retrospective multicenter cohorts (54%). Organ-specific responses were most favorable in gastrointestinal (52%) and joint/fascia (52%) involvement, but notably poor in lung cGvHD (25%). Prior ruxolitinib exposure was associated with lower ORR, while concurrent use and disease severity were not. The pooled overall survival was 87%, and failure-free survival was 57%. Adverse events were common but generally manageable; serious drug-related events occurred in ≤13% of patients, with Grade ≥3 pneumonia/lung infections in up to 17%. CONCLUSIONS: Belumosudil demonstrates promising efficacy and a favorable safety profile in refractory cGvHD. Our findings support further investigation in earlier treatment and disease course.
No takes yet. Share an insight, caveat, or question.
Rathje et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: